Jacobio's KRAS G12C and SHP2 therapy published in The Lancet

Jacobio Pharmaceuticals Group's self-developed KRAS G12C inhibitor glecirasib in combination with the SHP2 inhibitor JAB-3312 (sitneprotafib) has been published in The Lancet Respiratory Medicine. This marks the first time comprehensive clinical data for an all-oral KRAS G12C + SHP2 inhibitor combination has appeared in this journal.

The open-label Phase 1/2a study, conducted in China, enrolled 171 patients with KRAS G12C–mutated non-small cell lung cancer (NSCLC), including 102 previously untreated patients. Results showed the combination achieved a 71% objective response rate (ORR) and 12.2 months median progression-free survival (mPFS) in the first-line population. This performance reportedly outperforms many other first-line KRAS G12C treatment regimens and demonstrates strong competitiveness against current first-line standard of care (immunotherapy plus chemotherapy) as a chemotherapy-free alternative.

A Phase III clinical trial for the KRAS G12C inhibitor in combination with SHP2 inhibitor has been initiated in China. This trial will directly compare the combination regimen with the current first-line standard of care, aiming to potentially make it the first SHP2-containing combination therapy to gain global approval.